MedscapeKEYNOTE-189: Chemotherapy Plus Immunotherapy Now a Viable Option for PD-L1 Low Expression Non-Small Cell …MedscapeThe hazard ratio (HR) for OS was 0.49 with a difference at 1 year in OS of about 20%—from over 49% in the control arm to nearly … Continue reading
Big Think (blog)Scientists are trying revive woolly mammoth DNA to fight climate changeBig Think (blog)But if scientists can successfully use gene-editing systems like CRISPR to introduce woolly mammoth genes to elephants, that might change. “It could … Continue reading
WebMD |
Men May Gain More From Cancer Immunotherapy
WebMD THURSDAY, May 17, 2018 (HealthDay News) — Male cancer patients seem to fare significantly better following immunotherapy treatment than female patients, new research indicates. “Both sex and gender can potentially affect the strength of the body’s … |
Popular Science |
Forget allergy shots. Try allergy toothpaste.
Popular Science Immunotherapy works a lot like a vaccine, which teaches the immune system how to respond to pathogens by safely mimicking an invasion, and the results are just as impressive. While allergy shots don’t typically cure existing allergies entirely, they … |
Boston Business Journal |
Viewpoint: China has the upper hand in cancer cell therapy
Boston Business Journal Cheers went up last August when the U.S. Food and Drug Administration approved the world’s first CAR–T cancer cell treatment, Novartis’ Kymriah, and again in October when it approved Gilead’s CAR–T treatment for non-Hodgkin’s lymphoma. In CAR–T … |
FierceBiotech |
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
FierceBiotech Novo Nordisk has talked up the progress of its Type 1 diabetes stem cell therapy program. With the diabetes project clearing milestones and moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly. Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborationsEndpoints News Novo expands type 1 diabetes R&Dpharmaphorum |
FierceBiotech |
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
FierceBiotech Novo Nordisk has talked up the progress of its Type 1 diabetes stem cell therapy program. With the diabetes project clearing milestones and moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly. Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborationsEndpoints News Novo expands type 1 diabetes R&Dpharmaphorum |